Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Ye...( MADISON N.J. Jan. 17 /- Wyeth Con...)

MADISON, N.J., Jan. 17 /PRNewswire/ -- Wyeth Consumer Healthcare, a division of Wyeth (NYSE: WYE), supports today's U.S. Food and Drug Administration's (FDA) decision to no longer recommend use of over-the-counter cough and cold products in children under age two.

"This decision is consistent with our voluntary removal in October 2007 of over-the-counter infant cough and cold products from the global market to help reduce dosing errors and overdoses in children who are most vulnerable to misuse of these medicines," says Cavan Redmond, President, Wyeth Consumer Healthcare.

Since October 2007, the Company has worked with retailers, health care professionals and the FDA to ensure that parents have the information they need to adapt to the new guidelines regarding use of these medicines in children under age two.
Wyeth Consumer Healthcare is also taking the following actions:

-- Communicating to healthcare professionals to no longer recommend

over-the-counter cough and cold products for children under age two

-- Changing labels for products that have dosing instructions for

children under age two to clarify that over-the-counter cough and cold

medicines should not be used for children under age two

-- Updating health care professional dosing charts to reflect the new "do

not use" instructions for children under age two

-- Adding the "do not use" instructions for children under age two to

marketing materials for Robitussin and Dimetapp products

It is important to note that Wyeth believes over-the-counter cough and cold products are safe for use in children ages two and older, as well as in adults, when used according to label directions
'/>"/>